The function of cholesterol as an ERRα agonist may provide the molecular basis and mechanistic insight into clinical studies suggesting that drugs able to lower cholesterol levels (i.e., statins) can be used to treat or prevent breast and prostate cancer. Here, ESRRA is linked to prostate cancer.